Barcelona

• Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and … Pending
  2025-521989-95-00 9 Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending
  2025-522019-40-00 9 relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+)
• REVITALISE Study Pending
  2025-522060-32-00 4 STEMI (ST elevated Myocardial Infarction)
• A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflamma … Pending
  2025-522076-85-00 4 Rheumatoid arthritis
• Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. Pending
  2025-522138-29-00 4 Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with n
• STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer Pending
  2025-522145-21-00 5 Metastatic hormone sensitive prostate cancer
• A PHASE 1/1B, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC … Pending
  2025-522148-42-00 1 Advanced Solid Tumours
• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Pending
  2025-522204-24-00 4 Drug-Related Side Effects and Adverse Reactions
• A clinical study to investigate the efficacy of tarlatamab in people with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has … Pending
  2025-522288-13-00 4 Patients with pretreated extensive-stage small cell lung cancer (ES-SC
• Phase 1/2 study to investigate the safety and preliminary efficacy of GSK5460025 alone or in combination with other anti-cancer agents in dM … Pending
  2025-522318-21-00 7 Neoplasms, Colorectal
• A clinical trial of ifinatamab deruxtecan in people under age 18 who have certain types of cancer (MK-9999-01D) Pending
  2025-522339-32-00 9 Neoplasm malignant
• A trial to compare treatment with surlorian (ARM210, S48168) to placebo in effects on muscle strength and safety in adults with autosomal do … Pending
  2025-522343-18-00 4 Autosomal Dominant RYR1-Related Myopathy
• An Open Label Study to Assess the Effect of Patient Use and Robustness on Tiotropium Bromide Spray 2.5μg, Soft Mist Inhaler device Pending
  2025-522412-16-00 3 Chronic obstructive pulmonary disease
• A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study Pending
  2025-522427-10-00 4 Germ Cell Tumors refractory to salvage chemotherapy
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending
  2025-522475-28-00 5 Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
• A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma Pending
  2025-522523-96-00 1 T-cell Non-Hodgkin Lymphoma
• A study to test if tenecteplase helps people to recover from an acute stroke when given more than 4.5 hours after the person was last seen w … Pending
  2025-522542-40-00 5 Acute Ischemic Stroke
• An Efficacy and Safety Study of Clemizole HCl in Patients with Lennox-Gastaut Syndrome Pending
  2025-522552-20-00 5 Lennox-Gastaut Syndrome
• Evaluation of the persistency of the preoperative anxiolytic effect of music therapy vs midazolam: electroencephalographic and clinical ana … Pending
  2025-522575-29-00 6 Preoperative anxiety
• A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerabi … Pending
  2025-522582-30-00 1 Alzheimer’s Disease
• Dose determination study of Phleum pratense allergenic extract for immunotherapy treatment, administered via sublingual route, standardized … Pending
  2025-522730-31-00 4 Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Carcinoma, Transitional Cell

Showing 169–192 of 3,391 trials